<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-19506" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part indexed="no" book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Chromaffin Cell Cancer (Archived)</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mubarik</surname>
            <given-names>Ateeq</given-names>
          </name>
          <aff>Oak hill hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Aeddula</surname>
            <given-names>Narothama R.</given-names>
          </name>
          <aff>Deaconess HS, IN University School Med</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ateeq Mubarik declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Narothama Aeddula declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-19506.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>The term pheochromocytoma first described by Mr. Pick in 1912. Pheochromocytoma is a tumor that arises from chromaffin cells present in the adrenal medulla or paraganglion cells. It named in this way as these tissues&#x000a0;have a special reaction on the application of a chromium salt. Dr. Charles Mayo presented the first case of pheochromocytoma in 1937 with a clinical diagnosis and therapeutic surgical resection.</p>
      </sec>
      <sec id="article-19506.s2" sec-type="Etiology">
        <title>Etiology</title>
        <p>In 90% of the cases, pheochromocytoma is sporadic, but in 10% of patients, it is familial and associated with syndromes like&#x000a0;Von Hippel&#x02013;Lindau syndrome, type 1 neurofibromatosis, and multiple endocrine neoplasia syndromes type IIA and type IIB with an autosomal dominant mode of transmission.<xref ref-type="bibr" rid="article-19506.r1">[1]</xref></p>
      </sec>
      <sec id="article-19506.s3" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Pheochromocytoma is a rare neuroendocrine disorder. Its incidence is&#x000a0;0.05 to 0.2% of hypertensive individuals.<xref ref-type="bibr" rid="article-19506.r2">[2]</xref><xref ref-type="bibr" rid="article-19506.r3">[3]</xref>&#x000a0;The annual incidence is approximately 0.8 per 100,000 person-years.<xref ref-type="bibr" rid="article-19506.r4">[4]</xref>&#x000a0;In the United States, it is diagnosed in about 2 to 8 people per every 1 million people.</p>
        <p>Its incidence is equal in both genders. It's usually diagnosed between the age of 30 to 50, but pheochromocytoma due to genetic predisposition can present earlier.</p>
      </sec>
      <sec id="article-19506.s4" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Pheochromocytoma is a catecholamine-secreting neuroendocrine tumor. It is 1 of the 3 types based on&#x000a0;secreting catecholamine.</p>
        <list list-type="bullet">
          <list-item>
            <p>Norepinephrine secreting tumor</p>
          </list-item>
          <list-item>
            <p>Epinephrine secreting tumor</p>
          </list-item>
          <list-item>
            <p>Norepinephrine and epinephrine secreting tumor</p>
          </list-item>
        </list>
        <p>Tumors secrete only norepinephrine, usually present with sustained hypertension.&#x000a0;Norepinephrine and epinephrine secreting tumors present with paroxysmal hypertension. Only epinephrine can cause hypotension instead of hypertension.<xref ref-type="bibr" rid="article-19506.r5">[5]</xref></p>
        <p>Due to catecholamine release, there is an increase in heart rate, systemic vascular resistance, inotropic effect, and a decrease&#x000a0;in venous compliance. In pheochromocytoma, there is orthostatic hypotension, as it is a volume-depleted type of hypertension.</p>
      </sec>
      <sec id="article-19506.s5" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Macroscopically, pheochromocytoma is&#x000a0;encapsulated and appears brown&#x000a0;to yellow and soft. It is comprised of cystic degeneration, patches of necrosis, or hemorrhage.</p>
        <p>Histopathological examination showed that pheochromocytoma is&#x000a0;composed&#x000a0;of large basophilic cells assembled as a nest; the cytoplasm comprises multiple granules with many large, pleomorphic, and bizarre nuclei. The nuclei have prominent nucleoli and coarse chromatin. Occasional intracytoplasmic hyaline globules positive for periodic acid&#x02013;Schiff stain are present. There is a thin rim of subcapsular lipid-rich adrenal tissue. There is no clear demarcation between the tumor cells and normal adrenal tissue.</p>
        <p>Hyperchromasia, nuclear pleomorphism, or capsular or vascular invasion may be present, but these are not a predictor of malignancy. Metastases to a different&#x000a0;site are the only indicator of malignancy.</p>
      </sec>
      <sec id="article-19506.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Pheochromocytoma&#x000a0;can be asymptomatic and&#x000a0;diagnosed by further workup of an adrenal incidentaloma. It can present with vague symptoms like a headache&#x000a0;(50%), palpitations (60%), and diaphoresis (50%) that can lead to a paroxysmal hypertensive crisis due to increased catecholamine production. Other associated symptoms include pallor (40%), nausea (40%), tremor, trembling, fatigue (40%), anxiety, fever, pain, and flushing (20%).<xref ref-type="bibr" rid="article-19506.r6">[6]</xref> Characteristically, these symptoms are paroxysmal and may be precipitated by abdominal exertion, such as heavy lifting or performing the Valsalva maneuver. Almost 90% of the population with pheochromocytoma has hypertension.&#x000a0; Pheochromocytoma follows the rule of 10, which means only 10% are malignant, 10% are extra-adrenal,&#x000a0;and 10% are bilateral, extra-abdominal, familial, pediatric, and without hypertension. Recently, the diagnosis of asymptomatic people with pheochromocytoma has increased due to modern imaging techniques and intensive genetic testing.</p>
        <p>Pheochromocytoma can also cause hyperglycemia (40%), lactic acidosis, and weight loss.</p>
      </sec>
      <sec id="article-19506.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>If there is clinical suspicion of a pheochromocytoma, then the initial assessment starts with biochemical laboratory testing.<xref ref-type="bibr" rid="article-19506.r7">[7]</xref>&#x000a0;Plasma-free metanephrine or 24-hour urinary fractioned&#x000a0;metanephrine testing is recommended;&#x000a0;both can be done as an initial screen. The sensitivity is almost the same between these two biochemical tests, but there is a difference in the specificity. The plasma test (89%) is more specific than a urine test (69%).<xref ref-type="bibr" rid="article-19506.r8">[8]</xref>&#x000a0;Urinary vanillylmandelic acid is also used, but it is not as sensitive (64%).</p>
        <p>The discussion above indicates that the best initial screening test is the plasma-free metanephrine biochemical test.<xref ref-type="bibr" rid="article-19506.r8">[8]</xref>&#x000a0;Amphetamines, ephedrine, tricyclic antidepressants,&#x000a0;and&#x000a0;cocaine can affect&#x000a0;plasma and urine metanephrine levels; therefore, abstinence of these substances has&#x000a0;been suggested prior to these biochemical tests.<xref ref-type="bibr" rid="article-19506.r9">[9]</xref>&#x000a0;It is recommended&#x000a0;that the clinician collect plasma samples on ice, with the patient&#x000a0;in a supine position and a fasting state, to decrease the incidence of false-positive results.<xref ref-type="bibr" rid="article-19506.r10">[10]</xref></p>
        <p>Once metanephrine levels are 4-fold high from the normal reference value, then the next goal is to localize the hormone-secreting tumor. The problem arises when the metanephrine levels are&#x000a0;minimally elevated or equivocal.<xref ref-type="bibr" rid="article-19506.r9">[9]</xref> In that circumstance, the clonidine suppression test can help with the diagnosis.<xref ref-type="bibr" rid="article-19506.r11">[11]</xref></p>
        <p>Computed tomography (CT) scan or magnetic&#x000a0;resonance imaging (MRI) can be used&#x000a0;for localizing the tumor. In certain conditions like pregnancy, contrast allergy, and the pediatric population,&#x000a0;MRI should be done&#x000a0;instead of a CT scan. These imaging modalities are sensitive but not specific. A 123I-labeled metaiodobenzylguanidine&#x000a0;(MIBG) scintigraphy is very&#x000a0;specific for catecholamine-secreting tumors. It not only helpful in differentiating between adrenal and paraganglionic tumors but also helps in revealing multiple lesions and metastases.<xref ref-type="bibr" rid="article-19506.r12">[12]</xref>&#x000a0;</p>
        <p>Positron emission tomography (PET)&#x000a0;scan is superior to MIBG, especially in the evaluation of metastatic disease.<xref ref-type="bibr" rid="article-19506.r13">[13]</xref>. So far, genetic testing depends on a case-to-case basis and shared decision-making. Indications for genetic testing include&#x000a0;a family history of catecholamine-producing&#x000a0;tumor, age less than 50 years old, multiple tumors&#x000a0;at different sites, metastases, or bilateral tumors.<xref ref-type="bibr" rid="article-19506.r14">[14]</xref></p>
      </sec>
      <sec id="article-19506.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The gold standard treatment of pheochromocytoma is surgical resection. An interprofessional team is required for management.<xref ref-type="bibr" rid="article-19506.r15">[15]</xref>&#x000a0;It is mandatory to block the catecholamine effect before surgery to prevent hypertensive crises and arrhythmias, even in patients who are normotensive or asymptomatic. There is no particular preference for one drug over another to prevent hypertensive crises. Any alpha-adrenoceptor antagonist, a calcium-channel&#x000a0;blocker, or&#x000a0;angiotensin-receptor blocker can be used.<xref ref-type="bibr" rid="article-19506.r16">[16]</xref>&#x000a0;Calcium channel&#x000a0;blockers or beta-adrenergic&#x000a0;blockers are&#x000a0;indicated for the prophylactic treatment of arrhythmias.<xref ref-type="bibr" rid="article-19506.r17">[17]</xref></p>
        <p>The surgical technique depends on the size and site of the tumor.<xref ref-type="bibr" rid="article-19506.r18">[18]</xref>&#x000a0;Usually, tumors less than 10 cm are removed by laparoscopic&#x000a0;surgery.<xref ref-type="bibr" rid="article-19506.r19">[19]</xref>&#x000a0;If there is bilateral disease, then selective&#x000a0;adrenal&#x000a0;medulla surgery&#x000a0;is suggested to prevent the need for the lifelong use of glucocorticoids, but this technique also increases the risk of recurrence.<xref ref-type="bibr" rid="article-19506.r20">[20]</xref><xref ref-type="bibr" rid="article-19506.r21">[21]</xref></p>
      </sec>
      <sec id="article-19506.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>There are a variety of diseases similar to pheochromocytoma in clinical presentation.</p>
        <p>
<bold>Endocrine</bold>
</p>
        <p>Hyperthyroidism, carcinoid tumor, hypoglycemia, medullary thyroid carcinoma,&#x000a0;mastocytosis, menopausal syndrome</p>
        <p>
<bold>Cardiovascular</bold>
</p>
        <p>Heart failure, arrhythmias, ischemic heart disease</p>
        <p>
<bold>Neurological</bold>
</p>
        <p>Migraine, stroke, epilepsy, meningioma, postural orthostatic tachycardia syndrome (POTS)</p>
        <p>
<bold>Miscellaneous</bold>
</p>
        <p>Porphyria, panic disorder or anxiety, factitious disorders (from the use of sympathomimetic drugs such as ephedrine), drug treatment (monoamine oxidase inhibitors, sympathomimetic drugs, withdrawal of clonidine), use of illegal drugs (cocaine)</p>
      </sec>
      <sec id="article-19506.s10" sec-type="Radiation Oncology">
        <title>Radiation Oncology</title>
        <p>MIBG negative metastatic tumors have a very poor prognosis.&#x000a0;123I-MIBG positive tumors&#x000a0;can be treated with MIBG therapy in the form of 131I-MIBG, which emits beta radiation. There is no reliable data about its efficacy due to the lack&#x000a0;of comparable study designs.</p>
      </sec>
      <sec id="article-19506.s11" sec-type="Medical Oncology">
        <title>Medical Oncology</title>
        <p>The metastatic pheochromocytoma has no curative treatments unless the site of disease is surgically resectable.&#x000a0;Ten percent of all catecholamine-secreting tumors are malignant and are histologically and biochemically the same as benign tumors.</p>
        <p>Palliative chemotherapy includes cyclophosphamide, vincristine, dacarbazine, and temozolomide, along with other symptomatic therapy can increase the median survival from 2 to 26 months.<xref ref-type="bibr" rid="article-19506.r22">[22]</xref>&#x000a0;Further studies regarding the use of sunitinib&#x000a0;(tyrosine kinase inhibitor) and mTOR inhibitors are underway.</p>
      </sec>
      <sec id="article-19506.s12" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Usually, surgery is curative for benign or non-metastatic tumors. Metastatic tumors have a 50% survival over 5 years.<xref ref-type="bibr" rid="article-19506.r15">[15]</xref></p>
      </sec>
      <sec id="article-19506.s13" sec-type="Complications">
        <title>Complications</title>
        <p>Pheochromocytoma can induce Takotsubo&#x000a0;syndrome.<xref ref-type="bibr" rid="article-19506.r23">[23]</xref></p>
        <p>Pheochromocytoma crisis (severe acute presentation of a catecholamine-induced hemodynamic instability causing end-organ damage). There are two types:</p>
        <list list-type="order">
          <list-item>
            <p>Type A: End organ damage&#x000a0;but in the absence&#x000a0;of shock</p>
          </list-item>
          <list-item>
            <p>Type B: End organ damage with shock</p>
          </list-item>
        </list>
        <p>Pheochromocytoma crisis though rare, can be a potentially life-threatening emergency. Crisis can occur spontaneously or precipitated by the administration of pharmacological agents, such as glucagon, ergotamine, and caffeine, tumor manipulation, micturition (urinary bladder pheochromocytoma), or foods that aggravate the release of catecholamines by the tumor.<xref ref-type="bibr" rid="article-19506.r15">[15]</xref><xref ref-type="bibr" rid="article-19506.r24">[24]</xref></p>
      </sec>
      <sec id="article-19506.s14" sec-type="Postoperative and Rehabilitation Care">
        <title>Postoperative and Rehabilitation Care</title>
        <p>There are no American guidelines regarding the follow-up of the patient postoperatively. It is suggested&#x000a0;that repeating biochemical tests be done after 14 days of tumor surgery. However, even if the result is normal, it does not&#x000a0;mean that the tumor is completely resected. If plasma-free metanephrine or urinary fractioned&#x000a0;metanephrine levels are elevated for about 3 months after surgical removal, this is&#x000a0;an indication&#x000a0;for repeat imaging.<xref ref-type="bibr" rid="article-19506.r21">[21]</xref></p>
        <p>European guidelines recommend annual, postoperative follow-up for 10 years with biochemical testing for any recurrence or metastasis. Patients who have familial pheochromocytoma should be followed annually&#x000a0;for a lifetime. These recommendations are for patients who have abnormal biochemical tests preoperatively. Chromogranin A measurement should be used in the population having normal,&#x000a0;preoperative,&#x000a0;biochemical tests.<xref ref-type="bibr" rid="article-19506.r21">[21]</xref></p>
      </sec>
      <sec id="article-19506.s15" sec-type="Consultations">
        <title>Consultations</title>
        <list list-type="bullet">
          <list-item>
            <p>Nephrology</p>
          </list-item>
          <list-item>
            <p>Endocrinology</p>
          </list-item>
          <list-item>
            <p>General or endocrine surgery</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19506.s16" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Pheochromocytoma is a rare neuroendocrine tumor with serious and lethal clinical and cardiovascular complications due to the effects of secreted catecholamines. There needs to be close coordination between the&#x000a0;primary care provider, nephrologist, and endocrinologist. In patients with diagnosed pheochromocytoma, all patients should undergo resection of the pheochromocytoma following medical preparation, and coordination with the general surgeon is highly recommended. Before surgery and preoperatively, a pharmacist should be involved. Perioperative and surgical nurses are essential for the care of these patients. Coordination of this interprofessional team will improve outcomes. [Level 5]</p>
      </sec>
      <sec id="article-19506.s17">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19506&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19506">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/19506/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=19506">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-19506.s18">
        <title>References</title>
        <ref id="article-19506.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bryant</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Farmer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kessler</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Townsend</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Nathanson</surname>
                <given-names>KL</given-names>
              </name>
            </person-group>
            <article-title>Pheochromocytoma: the expanding genetic differential diagnosis.</article-title>
            <source>J Natl Cancer Inst</source>
            <year>2003</year>
            <month>Aug</month>
            <day>20</day>
            <volume>95</volume>
            <issue>16</issue>
            <fpage>1196</fpage>
            <page-range>1196-204</page-range>
            <pub-id pub-id-type="pmid">12928344</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19506.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blake</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Kalra</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Maher</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Sahani</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Sweeney</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Mueller</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Hahn</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Boland</surname>
                <given-names>GW</given-names>
              </name>
            </person-group>
            <article-title>Pheochromocytoma: an imaging chameleon.</article-title>
            <source>Radiographics</source>
            <year>2004</year>
            <month>Oct</month>
            <volume>24 Suppl 1</volume>
            <fpage>S87</fpage>
            <page-range>S87-99</page-range>
            <pub-id pub-id-type="pmid">15486252</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19506.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arora</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vargo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lupetin</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>Computed tomography appearance of spontaneous adrenal hemorrhage in a pheochromocytoma.</article-title>
            <source>Clin Imaging</source>
            <year>2009</year>
            <season>Jul-Aug</season>
            <volume>33</volume>
            <issue>4</issue>
            <fpage>314</fpage>
            <page-range>314-7</page-range>
            <pub-id pub-id-type="pmid">19559356</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19506.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beard</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Sheps</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Kurland</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>Carney</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Lie</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979.</article-title>
            <source>Mayo Clin Proc</source>
            <year>1983</year>
            <month>Dec</month>
            <volume>58</volume>
            <issue>12</issue>
            <fpage>802</fpage>
            <page-range>802-4</page-range>
            <pub-id pub-id-type="pmid">6645626</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19506.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Page</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Raker</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Berberich</surname>
                <given-names>FR</given-names>
              </name>
            </person-group>
            <article-title>Pheochromocytoma with predominant epinephrine secretion.</article-title>
            <source>Am J Med</source>
            <year>1969</year>
            <month>Oct</month>
            <volume>47</volume>
            <issue>4</issue>
            <fpage>648</fpage>
            <page-range>648-52</page-range>
            <pub-id pub-id-type="pmid">4390418</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19506.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Slywotzky</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Lavelle</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Garcia</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Cystic pheochromocytoma.</article-title>
            <source>Radiographics</source>
            <year>2002</year>
            <season>Jul-Aug</season>
            <volume>22</volume>
            <issue>4</issue>
            <fpage>935</fpage>
            <page-range>935-40</page-range>
            <pub-id pub-id-type="pmid">12110724</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19506.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lenders</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Duh</surname>
                <given-names>QY</given-names>
              </name>
              <name>
                <surname>Eisenhofer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gimenez-Roqueplo</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Grebe</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Murad</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Naruse</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pacak</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>WF</given-names>
              </name>
              <collab>Endocrine Society</collab>
            </person-group>
            <article-title>Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>99</volume>
            <issue>6</issue>
            <fpage>1915</fpage>
            <page-range>1915-42</page-range>
            <pub-id pub-id-type="pmid">24893135</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19506.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lenders</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Pacak</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Walther</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Linehan</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Mannelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Friberg</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Keiser</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Eisenhofer</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Biochemical diagnosis of pheochromocytoma: which test is best?</article-title>
            <source>JAMA</source>
            <year>2002</year>
            <month>Mar</month>
            <day>20</day>
            <volume>287</volume>
            <issue>11</issue>
            <fpage>1427</fpage>
            <page-range>1427-34</page-range>
            <pub-id pub-id-type="pmid">11903030</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19506.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eisenhofer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Walther</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Friberg</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lenders</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Keiser</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Pacak</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2003</year>
            <month>Jun</month>
            <volume>88</volume>
            <issue>6</issue>
            <fpage>2656</fpage>
            <page-range>2656-66</page-range>
            <pub-id pub-id-type="pmid">12788870</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19506.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pacak</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Eisenhofer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ahlman</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bornstein</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Gimenez-Roqueplo</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Grossman</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Kimura</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mannelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McNicol</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Tischler</surname>
                <given-names>AS</given-names>
              </name>
              <collab>International Symposium on Pheochromocytoma</collab>
            </person-group>
            <article-title>Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005.</article-title>
            <source>Nat Clin Pract Endocrinol Metab</source>
            <year>2007</year>
            <month>Feb</month>
            <volume>3</volume>
            <issue>2</issue>
            <fpage>92</fpage>
            <page-range>92-102</page-range>
            <pub-id pub-id-type="pmid">17237836</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19506.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bravo</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Tarazi</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Fouad</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Vidt</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Gifford</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>Clonidine-suppression test: a useful aid in the diagnosis of pheochromocytoma.</article-title>
            <source>N Engl J Med</source>
            <year>1981</year>
            <month>Sep</month>
            <day>10</day>
            <volume>305</volume>
            <issue>11</issue>
            <fpage>623</fpage>
            <page-range>623-6</page-range>
            <pub-id pub-id-type="pmid">7266587</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19506.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Furuta</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kiyota</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yoshigoe</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hasegawa</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ohishi</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis of pheochromocytoma using [123I]-compared with [131I]-metaiodobenzylguanidine scintigraphy.</article-title>
            <source>Int J Urol</source>
            <year>1999</year>
            <month>Mar</month>
            <volume>6</volume>
            <issue>3</issue>
            <fpage>119</fpage>
            <page-range>119-24</page-range>
            <pub-id pub-id-type="pmid">10226821</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19506.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mann</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>Link</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Pham</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pickett</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Byrd</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Kinahan</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Krohn</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Mankoff</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>[11C]metahydroxyephedrine and [18F]fluorodeoxyglucose positron emission tomography improve clinical decision making in suspected pheochromocytoma.</article-title>
            <source>Ann Surg Oncol</source>
            <year>2006</year>
            <month>Feb</month>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>187</fpage>
            <page-range>187-97</page-range>
            <pub-id pub-id-type="pmid">16418883</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19506.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amar</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bertherat</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Baudin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ajzenberg</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bressac-de Paillerets</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Chabre</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Chamontin</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Delemer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Giraud</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Murat</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Niccoli-Sire</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Richard</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rohmer</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Sadoul</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Strompf</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Schlumberger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bertagna</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Plouin</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Jeunemaitre</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Gimenez-Roqueplo</surname>
                <given-names>AP</given-names>
              </name>
            </person-group>
            <article-title>Genetic testing in pheochromocytoma or functional paraganglioma.</article-title>
            <source>J Clin Oncol</source>
            <year>2005</year>
            <month>Dec</month>
            <day>01</day>
            <volume>23</volume>
            <issue>34</issue>
            <fpage>8812</fpage>
            <page-range>8812-8</page-range>
            <pub-id pub-id-type="pmid">16314641</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19506.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lenders</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Eisenhofer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mannelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pacak</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Phaeochromocytoma.</article-title>
            <source>Lancet</source>
            <year>2005</year>
            <month>Aug</month>
            <day>20-26</day>
            <volume>366</volume>
            <issue>9486</issue>
            <fpage>665</fpage>
            <page-range>665-75</page-range>
            <pub-id pub-id-type="pmid">16112304</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19506.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Proye</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Thevenin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cecat</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Petillot</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Carnaille</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Verin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sautier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Racadot</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Exclusive use of calcium channel blockers in preoperative and intraoperative control of pheochromocytomas: hemodynamics and free catecholamine assays in ten consecutive patients.</article-title>
            <source>Surgery</source>
            <year>1989</year>
            <month>Dec</month>
            <volume>106</volume>
            <issue>6</issue>
            <fpage>1149</fpage>
            <page-range>1149-54</page-range>
            <pub-id pub-id-type="pmid">2588118</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19506.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bravo</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Tagle</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Pheochromocytoma: state-of-the-art and future prospects.</article-title>
            <source>Endocr Rev</source>
            <year>2003</year>
            <month>Aug</month>
            <volume>24</volume>
            <issue>4</issue>
            <fpage>539</fpage>
            <page-range>539-53</page-range>
            <pub-id pub-id-type="pmid">12920154</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19506.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Plouin</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Chatellier</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fofol</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Corvol</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Tumor recurrence and hypertension persistence after successful pheochromocytoma operation.</article-title>
            <source>Hypertension</source>
            <year>1997</year>
            <month>May</month>
            <volume>29</volume>
            <issue>5</issue>
            <fpage>1133</fpage>
            <page-range>1133-9</page-range>
            <pub-id pub-id-type="pmid">9149678</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19506.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Janetschek</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Finkenstedt</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gasser</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Waibel</surname>
                <given-names>UG</given-names>
              </name>
              <name>
                <surname>Peschel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bartsch</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Neumann</surname>
                <given-names>HP</given-names>
              </name>
            </person-group>
            <article-title>Laparoscopic surgery for pheochromocytoma: adrenalectomy, partial resection, excision of paragangliomas.</article-title>
            <source>J Urol</source>
            <year>1998</year>
            <month>Aug</month>
            <volume>160</volume>
            <issue>2</issue>
            <fpage>330</fpage>
            <page-range>330-4</page-range>
            <pub-id pub-id-type="pmid">9679871</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19506.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brunt</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Lairmore</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Doherty</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Quasebarth</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>DeBenedetti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Moley</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Adrenalectomy for familial pheochromocytoma in the laparoscopic era.</article-title>
            <source>Ann Surg</source>
            <year>2002</year>
            <month>May</month>
            <volume>235</volume>
            <issue>5</issue>
            <fpage>713</fpage>
            <page-range>713-20; discussion 720-1</page-range>
            <pub-id pub-id-type="pmid">11981218</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19506.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Plouin</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Amar</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Dekkers</surname>
                <given-names>OM</given-names>
              </name>
              <name>
                <surname>Fassnacht</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gimenez-Roqueplo</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Lenders</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Lussey-Lepoutre</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Steichen</surname>
                <given-names>O</given-names>
              </name>
              <collab>Guideline Working Group</collab>
            </person-group>
            <article-title>European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma.</article-title>
            <source>Eur J Endocrinol</source>
            <year>2016</year>
            <month>May</month>
            <volume>174</volume>
            <issue>5</issue>
            <fpage>G1</fpage>
            <page-range>G1-G10</page-range>
            <pub-id pub-id-type="pmid">27048283</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19506.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Deutschbein</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fassnacht</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Weismann</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Reincke</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mann</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Petersenn</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Treatment of malignant phaeochromocytoma with a combination of cyclophosphamide, vincristine and dacarbazine: own experience and overview of the contemporary literature.</article-title>
            <source>Clin Endocrinol (Oxf)</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>82</volume>
            <issue>1</issue>
            <fpage>84</fpage>
            <page-range>84-90</page-range>
            <pub-id pub-id-type="pmid">25143180</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19506.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Madias</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Recurrence, lingering recovery course, mild variants, and "chronic" forms, of takotsubo syndrome.</article-title>
            <source>Int J Cardiol</source>
            <year>2016</year>
            <month>Oct</month>
            <day>01</day>
            <volume>220</volume>
            <fpage>70</fpage>
            <page-range>70-1</page-range>
            <pub-id pub-id-type="pmid">27372046</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19506.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hosseinnezhad</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Black</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Aeddula</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Adhikari</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Trivedi</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Glucagon-induced pheochromocytoma crisis.</article-title>
            <source>Endocr Pract</source>
            <year>2011</year>
            <season>May-Jun</season>
            <volume>17</volume>
            <issue>3</issue>
            <fpage>e51</fpage>
            <page-range>e51-4</page-range>
            <pub-id pub-id-type="pmid">21324811</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
